BRIEF published on 05/13/2026 at 08:35, 4 months 4 days ago Inventiva presents its research on lanifibranor at the EASL Congress 2026 Biopharmaceutical Inventiva MASH Lanifibranor EASL Congress 2026
BRIEF published on 05/13/2026 at 08:35, 4 months 4 days ago Inventiva to Present Abstracts at EASL Congress 2026 Biopharmaceutical Research Inventiva Lanifibranor MASH Treatment EASL Congress 2026
PRESS RELEASE published on 05/13/2026 at 08:30, 4 months 4 days ago Inventiva to Present Abstracts at the EASL Congress 2026 Inventiva to present two abstracts at EASL Congress 2026 highlighting Lanifibranor's impact on MASH treatment. Lanifibranor, a pan-PPAR agonist, shows promising results in clinical trials Clinical Trials Inventiva Lanifibranor MASH Treatment EASL Congress 2026
BRIEF published on 04/22/2026 at 22:05, 4 months 25 days ago Inventiva strengthens its leadership for phase 3 of lanifibranor Appointment Biopharmaceutical Direction Phase 3 Lanifibranor
BRIEF published on 04/22/2026 at 22:05, 4 months 25 days ago Inventiva Bolsters Executive Team as It Nears Key Phase 3 Data Milestone Phase 3 Trial Lanifibranor Leadership Expansion MASH Treatment Inventiva Biopharmaceutical
PRESS RELEASE published on 04/22/2026 at 22:00, 4 months 25 days ago Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor Inventiva strengthens leadership team with new key hires for lanifibranor Phase 3 data readout, bolstering expertise in finance, legal, and HR to drive growth and commercialization Growth Leadership Team Phase 3 Inventiva Lanifibranor
BRIEF published on 04/08/2026 at 22:05, 5 months 9 days ago Inventiva files its Universal Registration Document and its 2025 Annual Report Annual Report Biopharmaceutical Registration Document Inventiva MASH
BRIEF published on 04/08/2026 at 22:05, 5 months 9 days ago Inventiva Submits 2025 Financial Reports to AMF and SEC Inventiva 2025 Financial Reports MASH Treatments Biopharmaceutical Developments AMF And SEC Filings
PRESS RELEASE published on 04/08/2026 at 22:00, 5 months 9 days ago Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F Inventiva files 2025 Universal Registration Document and Annual Report on Form 20-F with AMF and SEC, focusing on MASH therapies Biopharmaceutical 2025 Filing Inventiva MASH
BRIEF published on 04/02/2026 at 15:55, 5 months 15 days ago JP Morgan Chase & Co. crosses the thresholds for participation in INVENTIVA Voting Rights Threshold Crossing JP Morgan Inventiva Equity Swap
Published on 09/18/2026 at 00:55, 33 minutes ago Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 00:25, 1 hour 3 minutes ago CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/17/2026 at 22:15, 3 hours 13 minutes ago Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/17/2026 at 22:15, 3 hours 13 minutes ago Vanta Attends 2026 All-In Summit in Los Angeles, a Leading Gathering of Business, Investment and Industry Leaders
Published on 09/17/2026 at 22:05, 3 hours 23 minutes ago Loop Industries Forms Strategic Alternatives Committee to Maximize Shareholder Value
Published on 09/17/2026 at 19:00, 6 hours 28 minutes ago Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Published on 09/17/2026 at 18:58, 6 hours 29 minutes ago EQS-Adhoc: H2APEX Group SCA: General Partner of H2APEX Group SCA resolves to prepare for the transfer of its stock exchange listing from the Regulated Market (Prime Standard) to the Scale segment of the Frankfur
Published on 09/17/2026 at 18:25, 7 hours 3 minutes ago Magentic raises $18M to build the AI workforce for the physical world
Published on 09/17/2026 at 18:10, 7 hours 18 minutes ago A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%
Published on 09/17/2026 at 17:46, 7 hours 42 minutes ago RBI categorically denies the allegations of short-seller report
Published on 09/17/2026 at 17:40, 7 hours 48 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 7 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 18 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
